March 16, 2021
Here is the article.
An experimental cancer treatment from Rubius Therapeutics (RUBY) showed early promise on Monday, leading RUBY stock to nearly double.
On the stock market today, RUBY stock skyrocketed 84.4% to 30.29.
The company tested its drug, known as RTX-240, in patients with solid tumors. The treatment led to partial responses in two patients — one with metastatic anal cancer and one with melanoma of the eye. Researchers deemed six other patients stable.
Chief Executive Pablo Cagnoni says he believes the results provide clinical validation of the company's technology. Rubius tests include cancer treatments using red blood cells engineered to mimic the immune system.
"The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary (effectiveness) data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer," he said in a written statement.
RUBY Stock Skyrockets
The results stoked RUBY stock to a record high.
Tumors shrank by 54% in one patient with metastatic anal cancer. A patient with melanoma of the eye also had cancerous lesions on the liver. The targeted lesion completely disappeared.
Both patients had previously worsened while receiving immunotherapy drugs that target the protein PD-1. Treatment with RTX-240 was still ongoing eight and four months after the data cutoff for the studies in anal cancer and melanoma, respectively.
Also bullish for RUBY stock, six other patients were considered stable following treatment. Four of those were stable for at least 12 weeks, Rubius said. Those patients had cancers of the lungs, soft tissue, pancreas and prostate.
The most common treatment-related side effects included fatigue, nausea, decreased appetite and joint pain. Five of the patients experienced immune-related side effects. More serious adverse events included inflammation of lung tissue, insufficient levels of a specific hormone and hypothyroidism.
No comments:
Post a Comment